TLE3 as a marker for chemotherapy
View Patent ↗Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
1. A method of identifying a breast cancer that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) identifying the patient's breast cancer as one that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
2. The method of claim 1 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected.
3. The method of claim 1 wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample.
4. The method of claim 1 , wherein the step of identifying comprises identifying the patient's breast cancer as one that will respond favorably to a chemotherapy treatment that includes a taxane.
5. The method of claim 4 , wherein the taxane is paclitaxel or docetaxel.
6. The method of claim 1 , further comprising administering a chemotherapy treatment that includes a taxane or taxane derivative to the breast cancer patient.
7. A method of identifying a breast cancer that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) identifying the patient's breast cancer as one that will respond favorably to a chemotherapy treatment that includes a taxane or taxane derivative,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
8. A method of predicting the likelihood that a breast cancer will respond to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) predicting that the patient's breast cancer will likely respond to a chemotherapy treatment that includes a taxane or taxane derivative,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
9. The method of claim 8 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected.
10. The method of claim 8 , wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample.
11. The method of claim 8 , wherein the step of predicting comprises predicting that the patient's breast cancer will likely respond to a chemotherapy treatment that includes a taxane.
12. The method of claim 11 , wherein the taxane is paclitaxel or docetaxel.
13. The method of claim 8 further comprising administering a chemotherapy treatment that includes a taxane or taxane derivative to the breast cancer patient.
14. A method of predicting the likelihood that a breast cancer will respond to a chemotherapy treatment that includes a taxane or taxane derivative, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast cancer patient, wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) predicting that the patient's breast cancer will likely respond to a chemotherapy treatment that includes a taxane or taxane derivative,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide, and the step of detecting comprises detecting the complex in the cancer sample.
15. A method of treating a breast, lung or ovarian cancer patient, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast, lung or ovarian cancer patient;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) administering a chemotherapy treatment that includes a taxane or taxane derivative to the patient,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with an antibody that binds TLE3 polypeptide thereby forming a complex comprising the antibody and TLE3 polypeptide and the step of detecting comprises detecting the complex in the cancer sample.
16. The method of claim 15 , wherein the step of detecting comprises quantifying a percentage of cells in which immunohistochemical staining for TLE3 polypeptide is detected.
17. The method of claim 15 , wherein the step of detecting comprises quantifying an intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample.
18. The method of claim 15 , wherein the cancer sample is obtained from a breast cancer patient.
19. The method of claim 15 , wherein the step of administering comprises administering a taxane.
20. The method of claim 19 , wherein the taxane is paclitaxel or docetaxel.
21. The method of claim 18 , wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers.
22. The method of claim 15 , wherein the cancer sample is obtained from a lung cancer patient.
23. The method of claim 22 , wherein the step of administering comprises administering a taxane.
24. The method of claim 23 , wherein the taxane is paclitaxel or docetaxel.
25. The method of claim 15 , wherein the cancer sample is obtained from an ovarian cancer patient.
26. The method of claim 25 , wherein the step of administering comprises administering a taxane.
27. The method of claim 26 , wherein the taxane is paclitaxel or docetaxel.
28. A method of treating a breast, lung or ovarian cancer patient, the method comprising:
(a) performing immunohistochemical staining for TLE3 polypeptide on a cancer sample obtained from a breast, lung or ovarian cancer patient;
(b) detecting a percentage and/or intensity of immunohistochemical staining for TLE3 polypeptide in the cancer sample, wherein the detected percentage and/or intensity is higher than a reference; and
(c) administering a chemotherapy treatment that includes a taxane or taxane derivative to the patient,
wherein the step of performing immunohistochemical staining comprises contacting the cancer sample with a primary antibody that binds TLE3 polypeptide and a labeled secondary antibody that binds the primary antibody thereby forming a complex comprising the primary antibody, secondary antibody and TLE3 polypeptide; and the step of detecting comprises detecting the complex in the cancer sample.
29. The method of claim 28 , wherein the cancer sample is obtained from a breast cancer patient, and the taxane is paclitaxel or docetaxel.
30. The method of claim 29 , wherein the breast cancer patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers.